Abstract
Systemic lupus erythematosus (SLE) is a potentially life-threatening autoimmune disease characterized by altered balance of activity between effector and regulatory CD4(+) T cells. The homeostasis of CD4(+) T cell subsets is regulated by interleukin (IL)-2, and reduced production of IL-2 by T cells is observed in individuals with SLE. Here we report that treatment with low-dose recombinant human IL-2 selectively modulated the abundance of regulatory T (Treg) cells, follicular helper T (TFH) cells and IL-17-producing helper T (TH17) cells, but not TH1 or TH2 cells, accompanied by marked reductions of disease activity in patients with SLE.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Animals
-
CD4-Positive T-Lymphocytes / drug effects
-
CD4-Positive T-Lymphocytes / immunology
-
Cell Proliferation / drug effects
-
Disease Models, Animal
-
Female
-
Humans
-
Interleukin-2 / administration & dosage*
-
Interleukin-2 / pharmacology
-
Interleukin-2 / therapeutic use
-
Lupus Erythematosus, Systemic / drug therapy*
-
Lupus Erythematosus, Systemic / immunology
-
Male
-
Mice
-
Middle Aged
-
Prospective Studies
-
T-Lymphocyte Subsets / drug effects
-
T-Lymphocyte Subsets / immunology
-
T-Lymphocytes, Helper-Inducer / drug effects
-
T-Lymphocytes, Helper-Inducer / immunology*
-
T-Lymphocytes, Regulatory / drug effects
-
T-Lymphocytes, Regulatory / immunology*
-
Th1 Cells / drug effects
-
Th1 Cells / immunology
-
Th17 Cells / drug effects
-
Th17 Cells / immunology
-
Th2 Cells / drug effects
-
Th2 Cells / immunology
-
Treatment Outcome
-
Young Adult